TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027

Benzinga Newsdesk www.benzinga.com Negative 92.0%

Neg 92% Neu 0% Pos 0%

Comments

No comments yet. Be the first!